Bevacizumab added to conventional induction chemotherapy for children with high risk neuroblastoma (BRAVEN trial) Authors: Jagdish Prasad Meena, Debasish Sahoo, Harshita Makkar, Sujata Bhattacharya, Aditya Kumar Gupta, Deepam Pushpam, Manisha Jana, Aanchal Kakkar, Bangkim Chandra Khangembam, Maroof Ahmad Khan, Narendra Kumar Chaudhary, Nidhi Chopra, Prashant Prabhakar, Amitabh Singh, Shilpa Khanna Arora, Nishant Verma, Sonali Mohapatra, Maharshi Trivedi, Parichay Singh, Vineeta Gupta, Pankaj Dwivedi, Sameer Bakhshi, Imteyaz Ahmad Khan, Lata Singh, Piali Mandal, Rachna Seth Published: 2026 ABSTRACT BackgroundDespite advances in multimodal therapy, high-risk neuroblastoma (HR-NB) continues to have poor outcomes. Response to induction chemotherapy is a key predictor of long-term survival, yet intensive multi-agent regimens have not substantially improved prognosis.ObjectivesThis study aims to evaluate the efficacy and safety of adding bevacizumab to conventional induction chemotherapy in HR-NB.MethodsThis prospective, multicenter, randomized controlled trial will enroll newly diagnosed high-risk neuroblastoma patients, randomized to receive either conventional induction chemotherapy alone (control) or bevacizumab plus conventional induction chemotherapy (intervention). Response to induction therapy will be assessed according to standard criteria, and patients achieving a complete or good partial response will proceed to autologous stem cell transplantation (ASCT). All participants will be followed for at least 2 years to evaluate event-free survival (EFS) and overall survival (OS). The primary outcome, response rate, will be reported as a proportion, and EFS and OS will be analyzed using Kaplan–Meier plots and log-rank tests. The secondary outcomes (toxicity and minimal residual disease) will be reported as proportions. Prognostic factors will be evaluated with univariate and multivariate Cox regression analyses.Expected outcomesThe study aims to demonstrate that adding bevacizumab to conventional induction chemotherapy improves response rates, increases the proportion of patients eligible for autologous stem cell transplantation (ASCT), and improves survival outcomes, with manageable toxicities.Trial registrationThis study is registered with the Clinical Trials Registry of India (CTRI/2024/09/074065, dated: 19/09/2024).Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s12672-026-05462-7. Introduction Neuroblastoma (NB) is the most common extracranial solid malignancy of childhood and accounts for approximately 15% of all pediatric cancer-related deaths [1]. Despite current multimodal treatment strategies, approximately 80% of patients achieve at least a partial response (PR) to induction chemotherapy, while end-of-induction complete response (CR) rates remain as low as 20% [2]. Moreover, approximately 15–20% of patients exhibit refractory or progressive disease (PD) by the completion of induction therapy [3, 4]. Although advances in intensive induction chemotherapy, surgical resection, myeloablative chemotherapy (MAC) followed by hematopoietic stem cell transplantation (HSCT), radiotherapy, and differentiation therapy with 13-cis-retinoic acid have led to incremental improvements in outcomes over the past three decades, the long-term overall survival (OS) for high-risk neuroblastoma remains below 50% [5–7]. The primary goal of induction therapy in NB is to eradicate detectable tumor burden and achieve a state of remission. The Society of Pediatric Oncology Europe Neuroblastoma Group (SIOPEN) continues to employ the rapid COJEC regimen [Cisplatin (C), Vincristine (O), Carboplatin (J), Etoposide (E), and Cyclophosphamide (C)] as the standard induction protocol for high-risk neuroblastoma (HR-NB). This regimen remains the preferred induction approach in contemporary European trials. Rapid COJEC consists of eight intensive chemotherapy cycles. Specifically, the schedule includes two courses of carboplatin–etoposide–vincristine (OJE), four courses of cisplatin–vincristine (OP), and two courses of vincristine–etoposide–cyclophosphamide (OEC), delivered at compressed 10-day intervals. This time-intensive regimen is designed to maximize cytoreduction while maintaining dose density [7, 8]. Incomplete metastatic response to induction therapy in high-risk neuroblastoma has been consistently associated with inferior clinical outcomes [9–11]. The bone marrow is one of the most frequent sites of metastasis in HR-NB. Persistent residual disease in the marrow following induction therapy, regardless of treatment strategy or intensity, is consistently associated with unfavorable outcomes [12, 13]. Patients demonstrating a poor response to induction therapy typically experience markedly inferior outcomes. The rationale of the study In high-risk neuroblastoma, the majority of patients do not attain a complete response. Even with intensive multimodal treatment strategies that include multi-agent induction chemotherapy, 5-year event-free survival remains unsatisfactory. Thus, the induction phase is a crucial component of therapy, as resistant clones may develop during this period, while persistent refractory residual disease remains a significant barrier to improved outcomes [14]. Further dose escalation of induction chemotherapy or intensification of consolidation with myeloablative therapy followed by autologous HSCT is constrained by significant toxicity [15]. Moreover, extended chemotherapy has not been shown to confer any meaningful improvement in survival outcomes in HR-NB [16]. Therefore, evaluating the efficacy and safety of incorporating a novel tumor-targeted therapy into the treatment paradigm for HR-NB is essential. The pro-angiogenic vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are believed to play a pivotal role in initiating tumor angiogenesis [17]. Angiogenesis is a critical driver of neuroblastoma progression, and increased tumor vascularity has been strongly associated with high-risk disease [18]. Elevated expression of VEGF and VEGFR has been shown to correlate with advanced stages of NB [19, 20]. Bevacizumab is a humanized monoclonal VEGF-neutralizing antibody, which was approved by the Food and Drug Administration (FDA) in 2004 for the treatment of metastatic malignancies [21], a development that has transformed therapeutic paradigms by improving overall and/or progression-free survival, thereby establishing bevacizumab as a standard component of care for multiple advanced malignancies [22]. Recently, the ITCC–SIOPEN BEACON-Neuroblastoma trial (ages 1–21 years) demonstrated that the addition of bevacizumab improved overall response rate and progression-free survival (PFS) in patients with relapsed or refractory neuroblastoma, as reported in the phase II cohort (n = 106) [23]. In another study, De Pasquale et al. evaluated bevacizumab in 17 pediatric patients with high-risk malignancies, including four with stage IV neuroblastoma [24]. Modak et al. reported that bevacizumab, when combined with irinotecan and temozolomide, demonstrated an acceptable safety profile in children with relapsed or refractory neuroblastoma [25]. This study aims to evaluate an anti-angio-invasive agent in combination with conventional induction therapy in patients with high-risk neuroblastoma. Study objectives The primary objective is to evaluate the efficacy of the addition of bevacizumab to conventional induction chemotherapy in high-risk neuroblastoma patients compared to induction chemotherapy alone. Secondary objectives are to investigate the safety of adding bevacizumab to chemotherapy compared with induction chemotherapy alone, and to compare minimal residual disease in blood and bone marrow at the end of induction therapy between the two groups. Patients and methods Study design This study is designed as a multicentric randomized controlled trial (Fig. 1). The design, conduct, analysis, and reporting of this randomized controlled trial adhere to the Consolidated Standards of Reporting Trials CONSORT guidelines. The completed CONSORT checklist is submitted as an additional file (Appendix 1), and the trial protocol is provided as a supplementary file (Appendix 2).Fig. 1Schematic representation of the BRAVEN Trial design. The control arm (RAPID COJEC) includes cisplatin, carboplatin, cyclophosphamide, vincristine, and etoposide. The intervention arm (RAPID COJEC + Bevacizumab) combines chemotherapy with anti-angiogenic therapy Schematic representation of the BRAVEN Trial design. The control arm (RAPID COJEC) includes cisplatin, carboplatin, cyclophosphamide, vincristine, and etoposide. The intervention arm (RAPID COJEC + Bevacizumab) combines chemotherapy with anti-angiogenic therapy Study setting This study will be conducted across ten pediatric oncology centers from different institutions involved in the care of children with cancer, with the All India Institute of Medical Sciences, New Delhi, India, acting as the central coordinating center. Recruitment will be undertaken at all participating sites, and all newly diagnosed patients with neuroblastoma will be screened for eligibility. Sample size estimation and sampling strategy With conventional induction chemotherapy (rapid COJEC), reported complete response and good partial response rates range from 63 to 74% [7, 26, 27]. Assuming an absolute improvement of 20% in the response rate with the addition of bevacizumab, based on a baseline estimate of 65%, and applying a two-sided alpha of 5% and a power of 80%, a total sample size of 162 patients (81 per arm) with high-risk neuroblastoma will be required for randomization. Participants eligibility criteria Children aged ≤ 18 years with newly diagnosed high-risk neuroblastoma will be considered eligible for enrollment after providing informed consent. Patients will be excluded if they fulfill any of the following conditions: inadequate peripheral blood or bone marrow samples for MRD evaluation; severe organ dysfunction at the time of randomization; previous history of malignant disease; prior receipt of at least one full cycle of chemotherapy for high-risk neuroblastoma or prior surgery for the current disease before randomization; poor performance status or a clinical condition rendering them unsuitable for intensive chemotherapy; previous or ongoing severe arterial thromboembolic events, including myocardial ischemia, cerebrovascular accident, or peripheral arterial thrombosis; history of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, or active gastrointestinal bleeding within the last 6 months; inherited bleeding disorders or clinically significant coagulopathy associated with an increased risk of bleeding; and current chronic inflammatory bowel disease or bowel obstruction. Screening and method of recruitment All newly diagnosed patients with neuroblastoma will be screened at participating centers, and those meeting the criteria for high-risk disease will be enrolled over a 3-year recruitment period. Information on eligible patients will be recorded in a screening proforma. After eligibility has been confirmed in accordance with the inclusion and exclusion criteria, parents or legally authorized representatives (LARs) will be invited to provide informed consent. The consent process will include a detailed explanation of the study rationale, procedures, potential benefits, and associated risks. Enrollment will be undertaken only after written informed consent has been obtained from the parent/LAR, along with assent from children aged above 7 years, with appropriate witnessing wherever required. For participants, whose parents /LARs are unable to read or write, consent may be provided using a left thumb impression. The overall study flow is depicted in Fig. 2.Fig. 2Study Flow (IR-NB: Intermediate risk NB, HR-NB: High-risk neuroblastoma) Study Flow (IR-NB: Intermediate risk NB, HR-NB: High-risk neuroblastoma) Randomization and allocation concealment All eligible patients with high-risk neuroblastoma will undergo randomization after enrollment and will be assigned to one of the following two study arms: Control group: Patients will receive conventional induction chemotherapy alone. Intervention group: Patients will receive bevacizumab in combination with conventional induction chemotherapy. The trial schema is presented in Fig. 3.Fig. 3TRIAL SCHEMA [COJEC: Cisplatin, Oncovin (vincristine), Carboplatin, Etoposide, Cyclophosphamide] TRIAL SCHEMA [COJEC: Cisplatin, Oncovin (vincristine), Carboplatin, Etoposide, Cyclophosphamide] Treatment plan: induction chemotherapy All enrolled patients will receive eight courses of the rapid COJEC induction regimen [7]. Patients in the intervention arm will also receive bevacizumab in addition to rapid COJEC. Upon completion of induction therapy, all patients will undergo standardized response assessment. Randomization will be conducted using computer-generated block randomization with variable block sizes to maintain balanced allocation across study arms. The randomization sequence is safeguarded by an individual independent of patient enrollment, intervention administration, and data analysis .Fig. 4Work plan for real-time based MRD detection (for minimal residual disease measurement) Work plan for real-time based MRD detection (for minimal residual disease measurement) The centralized randomization sequence has been provided to a designated individual in the Department of Biostatistics at the All India Institute of Medical Sciences, New Delhi, India, who will prepare sequentially numbered, sealed envelopes corresponding to each randomized patient. Another designated person will open the next envelope in sequence upon patient enrollment. All opened envelopes, along with documentation of patient allocation and the date of envelope opening, will be securely archived for future verification. Allocation concealment will be ensured by using identical, opaque, sealed envelopes. Children in both study arms will be followed at regular clinical intervals to assess the primary and secondary endpoints. Clinical evaluation and data collection Details of all children who meet the inclusion and exclusion criteria at each collaborating center will be recorded on a pre-designed case record form (CRF) proforma. Baseline clinical data, including presenting symptoms, physical examination findings, and relevant laboratory parameters, will be documented. Pre-treatment investigations Pre-treatment investigations will be used to confirm patient eligibility and determine disease staging. All required laboratory evaluations must be completed within 1 week prior to the initiation of chemotherapy, and radiological assessments must be performed within two weeks of the planned start of chemotherapy (Table 1).Table 1Pre-treatment investigations of neuroblastoma patientsType of assessmentTiming▪ Written consent/assent▪ Before all specific procedures of the study▪ Diagnosis, medical history, demographics▪ Before inclusion in the studyClinical Examination▪ Full physical examination▪ Height, weight, body surface▪ Vital signs: Blood pressure, heart rate, temperature▪ Complete systemic examination▪ To be examined ≤ 1 week prior to the first chemotherapyLaboratory evaluation▪ Complete blood count: Total leukocyte count (TLC), hemoglobin (HB), differential count, and platelet count▪ Blood chemistry: Urea, creatinine, total protein, albumin, Ca+, phosphorus and electrolytes (sodium, potassium), SGOT, SGPT, total bilirubin, alkaline phosphatase, ferritin, and LDH▪ Urine VMA▪ To be done ≤ 1 week before the first chemotherapyRadiological /Nuclear scans and other investigations▪ Computed Tomography (CT) scan or Magnetic Resonance Imaging (MRI) of the primary site. Volume estimation should be attempted by providing the maximum sagittal, coronal, and axial diameters▪ CT scan: For the assessment of thoracic or abdominal tumors▪ MRI scan: For the assessment of spine and brain tumors▪ MIBG scan or FDG-PET** scan recommended▪ Bilateral bone marrow aspiration and bone marrow biopsy recommended▪ To be done ≤ 2 weeks prior to the first chemotherapySGOT: Glutamic Oxaloacetic Transaminase, SGPT: Serum Glutamic Pyruvic Transaminase, VMA-Vanillylmandelic acid, LDH: Lactate dehydrogenase, **PET-CT to be done only in cases of MIBG not avid Table 1Pre-treatment investigations of neuroblastoma patientsType of assessmentTiming▪ Written consent/assent▪ Before all specific procedures of the study▪ Diagnosis, medical history, demographics▪ Before inclusion in the studyClinical Examination▪ Full physical examination▪ Height, weight, body surface▪ Vital signs: Blood pressure, heart rate, temperature▪ Complete systemic examination▪ To be examined ≤ 1 week prior to the first chemotherapyLaboratory evaluation▪ Complete blood count: Total leukocyte count (TLC), hemoglobin (HB), differential count, and platelet count▪ Blood chemistry: Urea, creatinine, total protein, albumin, Ca+, phosphorus and electrolytes (sodium, potassium), SGOT, SGPT, total bilirubin, alkaline phosphatase, ferritin, and LDH▪ Urine VMA▪ To be done ≤ 1 week before the first chemotherapyRadiological /Nuclear scans and other investigations▪ Computed Tomography (CT) scan or Magnetic Resonance Imaging (MRI) of the primary site. Volume estimation should be attempted by providing the maximum sagittal, coronal, and axial diameters▪ CT scan: For the assessment of thoracic or abdominal tumors▪ MRI scan: For the assessment of spine and brain tumors▪ MIBG scan or FDG-PET** scan recommended▪ Bilateral bone marrow aspiration and bone marrow biopsy recommended▪ To be done ≤ 2 weeks prior to the first chemotherapySGOT: Glutamic Oxaloacetic Transaminase, SGPT: Serum Glutamic Pyruvic Transaminase, VMA-Vanillylmandelic acid, LDH: Lactate dehydrogenase, **PET-CT to be done only in cases of MIBG not avid Pre-treatment investigations of neuroblastoma patients Clinical Examination ▪ Full physical examination ▪ Height, weight, body surface ▪ Vital signs: Blood pressure, heart rate, temperature ▪ Complete systemic examination Laboratory evaluation ▪ Complete blood count: Total leukocyte count (TLC), hemoglobin (HB), differential count, and platelet count ▪ Blood chemistry: Urea, creatinine, total protein, albumin, Ca+, phosphorus and electrolytes (sodium, potassium), SGOT, SGPT, total bilirubin, alkaline phosphatase, ferritin, and LDH ▪ Urine VMA Radiological /Nuclear scans and other investigations ▪ Computed Tomography (CT) scan or Magnetic Resonance Imaging (MRI) of the primary site. Volume estimation should be attempted by providing the maximum sagittal, coronal, and axial diameters ▪ CT scan: For the assessment of thoracic or abdominal tumors ▪ MRI scan: For the assessment of spine and brain tumors ▪ MIBG scan or FDG-PET** scan recommended ▪ Bilateral bone marrow aspiration and bone marrow biopsy recommended SGOT: Glutamic Oxaloacetic Transaminase, SGPT: Serum Glutamic Pyruvic Transaminase, VMA-Vanillylmandelic acid, LDH: Lactate dehydrogenase, **PET-CT to be done only in cases of MIBG not avid Response assessment at the end of induction therapy: The response evaluation strategy is outlined in Table 2.Table 2Assessment at the end of induction chemotherapyType of assessmentTimingClinical Examination▪ Full physical examination▪ Height, weight, body surface▪ Vital signs: Blood pressure, heart rate, temperature▪ Complete systemic examination▪ To be examined 3 weeks after the last chemotherapyLaboratory evaluation▪ Complete blood count: Total leukocyte count (TLC), hemoglobin (HB), differential count, and platelet count▪ Blood chemistry: Urea, creatinine, total protein, albumin, Ca + , phosphorus and electrolytes (sodium, potassium), SGOT, SGPT, total bilirubin, alkaline phosphatase, LDH▪ To be performed 3 weeks after the last chemotherapyRadiological /Nuclear scans and other investigations▪ Computed Tomography (CT) scan or Magnetic Resonance Imaging (MRI) of the primary site. Volume estimation should be attempted by providing the maximum sagittal, coronal, and axial diameters▪ CT scan: For the assessment of thoracic or abdominal tumors▪ MRI scan: For the assessment of spine and brain tumors▪ MIBG scan or FDG-PET scan recommended▪ Bilateral bone marrow aspiration and bone marrow biopsy recommendedMandatory▪ To be performed 3 weeks after the last cycle of chemotherapy(exception: documented previous disease progression)Treatment details:▪ Details of chemotherapy protocol (initiation and completion of chemotherapy)▪ Response status after completion of induction chemotherapy: complete response (CR), good partial response (GPR), partial response (PR), stable disease (SD), progressive (PD)▪ Survival outcome: Event-free survival (EFS) and overall survival (OS)▪ At the time of enrollment, at the start of induction chemotherapy and,▪ At response evaluation (post-induction) Table 2Assessment at the end of induction chemotherapyType of assessmentTimingClinical Examination▪ Full physical examination▪ Height, weight, body surface▪ Vital signs: Blood pressure, heart rate, temperature▪ Complete systemic examination▪ To be examined 3 weeks after the last chemotherapyLaboratory evaluation▪ Complete blood count: Total leukocyte count (TLC), hemoglobin (HB), differential count, and platelet count▪ Blood chemistry: Urea, creatinine, total protein, albumin, Ca + , phosphorus and electrolytes (sodium, potassium), SGOT, SGPT, total bilirubin, alkaline phosphatase, LDH▪ To be performed 3 weeks after the last chemotherapyRadiological /Nuclear scans and other investigations▪ Computed Tomography (CT) scan or Magnetic Resonance Imaging (MRI) of the primary site. Volume estimation should be attempted by providing the maximum sagittal, coronal, and axial diameters▪ CT scan: For the assessment of thoracic or abdominal tumors▪ MRI scan: For the assessment of spine and brain tumors▪ MIBG scan or FDG-PET scan recommended▪ Bilateral bone marrow aspiration and bone marrow biopsy recommendedMandatory▪ To be performed 3 weeks after the last cycle of chemotherapy(exception: documented previous disease progression)Treatment details:▪ Details of chemotherapy protocol (initiation and completion of chemotherapy)▪ Response status after completion of induction chemotherapy: complete response (CR), good partial response (GPR), partial response (PR), stable disease (SD), progressive (PD)▪ Survival outcome: Event-free survival (EFS) and overall survival (OS)▪ At the time of enrollment, at the start of induction chemotherapy and,▪ At response evaluation (post-induction) Assessment at the end of induction chemotherapy Clinical Examination ▪ Full physical examination ▪ Height, weight, body surface ▪ Vital signs: Blood pressure, heart rate, temperature ▪ Complete systemic examination Laboratory evaluation ▪ Complete blood count: Total leukocyte count (TLC), hemoglobin (HB), differential count, and platelet count ▪ Blood chemistry: Urea, creatinine, total protein, albumin, Ca + , phosphorus and electrolytes (sodium, potassium), SGOT, SGPT, total bilirubin, alkaline phosphatase, LDH Radiological /Nuclear scans and other investigations ▪ Computed Tomography (CT) scan or Magnetic Resonance Imaging (MRI) of the primary site. Volume estimation should be attempted by providing the maximum sagittal, coronal, and axial diameters ▪ CT scan: For the assessment of thoracic or abdominal tumors ▪ MRI scan: For the assessment of spine and brain tumors ▪ MIBG scan or FDG-PET scan recommended ▪ Bilateral bone marrow aspiration and bone marrow biopsy recommended Mandatory ▪ To be performed 3 weeks after the last cycle of chemotherapy (exception: documented previous disease progression) Treatment details: ▪ Details of chemotherapy protocol (initiation and completion of chemotherapy) ▪ Response status after completion of induction chemotherapy: complete response (CR), good partial response (GPR), partial response (PR), stable disease (SD), progressive (PD) ▪ Survival outcome: Event-free survival (EFS) and overall survival (OS) ▪ At the time of enrollment, at the start of induction chemotherapy and, ▪ At response evaluation (post-induction) Diagnostic criteria for neuroblastoma The diagnosis of neuroblastoma will be established using standard morphological and immunohistochemical criteria. On histopathological examination, neuroblastoma is characterized by small round blue tumor cells with hyperchromatic nuclei and scant cytoplasm, variably associated with neuropil, Homer–Wright rosettes, and Schwannian stroma. Immunohistochemically, the tumor typically expresses neural markers, including synaptophysin, chromogranin A, and PHOX2B, of which PHOX2B is considered the most specific. Sample collection for MRD estimation Peripheral blood (2.5 mL) and bone marrow (2 mL) samples will be collected from enrolled patients at two time points: baseline (before initiation of therapy) and post-therapy (after induction therapy). Blood samples will be collected in PAXgene Blood RNA Tubes and PAXgene Bone Marrow RNA Tubes, respectively, to ensure immediate stabilization of intracellular RNA. Total RNA will be extracted using the PAXgene Blood RNA Kit, quantified using spectrophotometry or fluorometry (Qubit), and assessed for integrity through agarose gel electrophoresis. Subsequently, RNA will be reverse-transcribed into cDNA for quantitative real-time PCR (qRT-PCR) analysis [4] (Fig. 4). SYBR Green chemistry will be employed to measure the expression of 25 target genes (Table 3), with fold changes calculated relative to expression levels in non-diseased children (controls).Table 3List of genes for minimal residual disease (MRD) detection1MYCNN-myc proto-oncogene protein2TERTTelomerase reverse transcriptase3TP53Tumor protein p534ATRXAlternative Lengthening of Telomeres5NRASNRAS Proto-Oncogene6PHOX2BPaired-like homeobox 2b7THTyrosine Hydroxylase8CHRNA3Cholinergic Receptor Nicotinic Alpha 3 Subunit9GAP43Growth-associated protein-4310POSTNPeriostin11PRRX1Paired related homeobox 112FMO3Flavin-containing monooxygenase 313DDCDopa Decarboxylase14DBHDopamine beta (β)-hydroxylase15ISL1Insulin gene enhancer protein ISL-116PTPN11Protein Tyrosine Phosphatase Non-Receptor Type 1117NBPF10NBPF Member 1018DNAH2Dynein Axonemal Heavy Chain 219DDX1DEAD-Box Helicase 120NBASNBAS Subunit Of NRZ Tethering Complex21FOXJ1Forkhead Box J122ALKALK Receptor Tyrosine Kinase23KIF1BΒKinesin Family Member 1B24BARD1BRCA1 Associated RING Domain 125AURKAAurora Kinase A Table 3List of genes for minimal residual disease (MRD) detection1MYCNN-myc proto-oncogene protein2TERTTelomerase reverse transcriptase3TP53Tumor protein p534ATRXAlternative Lengthening of Telomeres5NRASNRAS Proto-Oncogene6PHOX2BPaired-like homeobox 2b7THTyrosine Hydroxylase8CHRNA3Cholinergic Receptor Nicotinic Alpha 3 Subunit9GAP43Growth-associated protein-4310POSTNPeriostin11PRRX1Paired related homeobox 112FMO3Flavin-containing monooxygenase 313DDCDopa Decarboxylase14DBHDopamine beta (β)-hydroxylase15ISL1Insulin gene enhancer protein ISL-116PTPN11Protein Tyrosine Phosphatase Non-Receptor Type 1117NBPF10NBPF Member 1018DNAH2Dynein Axonemal Heavy Chain 219DDX1DEAD-Box Helicase 120NBASNBAS Subunit Of NRZ Tethering Complex21FOXJ1Forkhead Box J122ALKALK Receptor Tyrosine Kinase23KIF1BΒKinesin Family Member 1B24BARD1BRCA1 Associated RING Domain 125AURKAAurora Kinase A List of genes for minimal residual disease (MRD) detection Duration of study: This study will complete enrollment over 36 months. Follow–up of enrolled patients Patients will undergo weekly clinical follow-up during treatment and, as required, according to their scheduled visits. Following initiation of induction therapy, both groups will be monitored for treatment-related adverse events. After completion of chemotherapy, patients will be followed every 3 months for at least 2 years from the date of diagnosis to assess survival outcomes, including event-free survival (EFS) and overall survival (OS). Definitions: High-risk neuroblastoma (HR-NB): HR-NB will be defined according to the revised International Neuroblastoma Risk Group Staging System (INRGSS) [28].Criteria for overall response: Overall response will be determined by integrating responses from individual disease components, including soft tissue, bone, and bone marrow involvement (Table 4).Complete Response (CR): Complete disappearance of disease at both primary and metastatic sites.Good Partial Response (GPR): According to the International Neuroblastoma Response Criteria (INRC), GPR is defined as ≥ 50% reduction in primary tumor volume, ≥ 50% reduction in skeletal MIBG uptake, and/or presence of ≤ 3 areas of abnormal skeletal uptake on MIBG scintigraphy, and/or residual tumor detected on bone marrow aspirate and trephine morphological examination.Poor Partial Response (PPR): It is defined according to the INRC as < 50% reduction in primary tumor volume, < 50% reduction in skeletal MIBG uptake and/or > 3 areas of abnormal skeletal uptake on MIBG scintigraphy, and/or persistence of tumor on bone marrow aspirate and trephine examination, including mixed response (MR), stable disease (SD), or progressive disease (PD) [29].Eligibility for High-Dose Therapy (HDT) and Stem Cell Transplant (SCT): Children who achieve metastatic complete response (CR) or metastatic good partial response (GPR) will be eligible for consolidation, including surgery, high-dose therapy followed by stem cell rescue, radiotherapy, and differentiation therapy.Event-Free Survival (EFS): Defined as the interval from neuroblastoma diagnosis to the occurrence of refractory disease, relapse, death, or the date of the most recent follow-up.Overall Survival (OS): Defined as the interval from diagnosis to death from any cause or the date of the last follow-up. Table 4Determination of overall response (soft tissue/ metastatic soft tissue and bone sites/bone marrow metastasis) [29]ResponseCriterionCR▪ All components meet criteria for CRPR▪ PR in at least one component and all other components are either CR, MD* (bone marrow), PR (soft tissue or bone), orNI†; no component with PDMR▪ PR or CR in at least one component but at least one other component with SD; no component with PDSD▪ SD in one component with no better than SD or NI† in any other component; no component with PDPD▪ Any component with PD*For bone marrow assessment only†Site not involved at study entry and remains uninvolvedCR, complete response; MD, minimal disease; MR, minor response; NI, not involved; PD, progressive disease; PR, partial response; SD, stable disease High-risk neuroblastoma (HR-NB): HR-NB will be defined according to the revised International Neuroblastoma Risk Group Staging System (INRGSS) [28]. High-risk neuroblastoma (HR-NB): HR-NB will be defined according to the revised International Neuroblastoma Risk Group Staging System (INRGSS) [28]. Criteria for overall response: Overall response will be determined by integrating responses from individual disease components, including soft tissue, bone, and bone marrow involvement (Table 4). Criteria for overall response: Overall response will be determined by integrating responses from individual disease components, including soft tissue, bone, and bone marrow involvement (Table 4). Complete Response (CR): Complete disappearance of disease at both primary and metastatic sites. Complete Response (CR): Complete disappearance of disease at both primary and metastatic sites. Good Partial Response (GPR): According to the International Neuroblastoma Response Criteria (INRC), GPR is defined as ≥ 50% reduction in primary tumor volume, ≥ 50% reduction in skeletal MIBG uptake, and/or presence of ≤ 3 areas of abnormal skeletal uptake on MIBG scintigraphy, and/or residual tumor detected on bone marrow aspirate and trephine morphological examination. Good Partial Response (GPR): According to the International Neuroblastoma Response Criteria (INRC), GPR is defined as ≥ 50% reduction in primary tumor volume, ≥ 50% reduction in skeletal MIBG uptake, and/or presence of ≤ 3 areas of abnormal skeletal uptake on MIBG scintigraphy, and/or residual tumor detected on bone marrow aspirate and trephine morphological examination. Poor Partial Response (PPR): It is defined according to the INRC as < 50% reduction in primary tumor volume, < 50% reduction in skeletal MIBG uptake and/or > 3 areas of abnormal skeletal uptake on MIBG scintigraphy, and/or persistence of tumor on bone marrow aspirate and trephine examination, including mixed response (MR), stable disease (SD), or progressive disease (PD) [29]. Poor Partial Response (PPR): It is defined according to the INRC as < 50% reduction in primary tumor volume, < 50% reduction in skeletal MIBG uptake and/or > 3 areas of abnormal skeletal uptake on MIBG scintigraphy, and/or persistence of tumor on bone marrow aspirate and trephine examination, including mixed response (MR), stable disease (SD), or progressive disease (PD) [29]. Eligibility for High-Dose Therapy (HDT) and Stem Cell Transplant (SCT): Children who achieve metastatic complete response (CR) or metastatic good partial response (GPR) will be eligible for consolidation, including surgery, high-dose therapy followed by stem cell rescue, radiotherapy, and differentiation therapy. Eligibility for High-Dose Therapy (HDT) and Stem Cell Transplant (SCT): Children who achieve metastatic complete response (CR) or metastatic good partial response (GPR) will be eligible for consolidation, including surgery, high-dose therapy followed by stem cell rescue, radiotherapy, and differentiation therapy. Event-Free Survival (EFS): Defined as the interval from neuroblastoma diagnosis to the occurrence of refractory disease, relapse, death, or the date of the most recent follow-up. Event-Free Survival (EFS): Defined as the interval from neuroblastoma diagnosis to the occurrence of refractory disease, relapse, death, or the date of the most recent follow-up. Overall Survival (OS): Defined as the interval from diagnosis to death from any cause or the date of the last follow-up. Overall Survival (OS): Defined as the interval from diagnosis to death from any cause or the date of the last follow-up. Table 4Determination of overall response (soft tissue/ metastatic soft tissue and bone sites/bone marrow metastasis) [29]ResponseCriterionCR▪ All components meet criteria for CRPR▪ PR in at least one component and all other components are either CR, MD* (bone marrow), PR (soft tissue or bone), orNI†; no component with PDMR▪ PR or CR in at least one component but at least one other component with SD; no component with PDSD▪ SD in one component with no better than SD or NI† in any other component; no component with PDPD▪ Any component with PD*For bone marrow assessment only†Site not involved at study entry and remains uninvolvedCR, complete response; MD, minimal disease; MR, minor response; NI, not involved; PD, progressive disease; PR, partial response; SD, stable disease Determination of overall response (soft tissue/ metastatic soft tissue and bone sites/bone marrow metastasis) [29] ▪ PR in at least one component and all other components are either CR, MD* (bone marrow), PR (soft tissue or bone), or NI†; no component with PD *For bone marrow assessment only †Site not involved at study entry and remains uninvolved CR, complete response; MD, minimal disease; MR, minor response; NI, not involved; PD, progressive disease; PR, partial response; SD, stable disease Reporting of adverse events All adverse events occurring during the study period, whether spontaneously reported by the patient or identified by the investigator or other study personnel, and considered related to the study treatment, will be comprehensively documented. For each event, records will include the nature of the event (diagnosis, signs, and symptoms), severity, date and time of onset and resolution, outcome, measures taken, and the investigator’s assessment of its causal relationship to the study treatment. All adverse events will be assessed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. [30]. Serious adverse events (SAEs) A serious adverse event (SAE) will be defined as any untoward medical occurrence that results in death, is life-threatening, results in persistent or significant disability/incapacity, or requires initial or prolonged hospitalization, regardless of its relationship to the study treatment. Furthermore, any event, including abnormal laboratory findings, unexpected adverse drug reactions, or any other adverse experience that, in the opinion of the investigator, is medically significant or represents a potential hazard, contraindication, side effect, or precaution, will be classified as an SAE. All deaths occurring while the patient is on study, including those due to disease progression or occurring within 30 days of the last administration of the study drug, will be reported as serious adverse events. Data collection and management Baseline characteristics and outcome measures will be systematically recorded in the CRF proforma. Individual CRF entries will be entered electronically into the database and periodically reviewed by the data management team to ensure accuracy and completeness. All study data will be maintained in REDCap. Following interim and final quality control checks, the database will be locked and exported for statistical analysis using appropriate software. Data safety monitoring board (DSMB) An independent central Data Safety Monitoring Board (DSMB), consisting of experts in randomized controlled trials and including a statistician, has been established to undertake regular review of study data. The DSMB will evaluate the risk–benefit profile of the intervention at prespecified intervals using validated data. The principal investigator (PI) will have the authority to temporarily suspend patient recruitment if the rate of severe toxicities exceeds 20%. Insurance and compensation Insurance coverage for trial-related injuries has been obtained from a third-party insurance provider in accordance with applicable regulatory requirements. Compensation for any trial-related harm will be provided in accordance with the insurance policy and national ethical guidelines. Study outcomes Primary outcome measures include the proportion of patients achieving a complete response or a good partial response following induction therapy, as well as survival outcomes (EFS and OS) in each study arm. Secondary outcome measures include the incidence and profile of treatment-related toxicities in both groups, and the assessment of minimal residual disease status after completion of induction therapy. Statistical analysis Descriptive statistics, including proportions (%), means (± SD), and medians (IQR), will be used to summarize baseline demographic and clinical characteristics of all patients. Response rates (CR/PR/GPR/PD) and treatment-related toxicities will be presented as proportions (%). Minimal residual disease (MRD) status at the end of induction will be reported as the proportion of patients with MRD-positive or MRD-negative disease. The association between categorical variables will be assessed using the chi-square test. Event-free survival (EFS) and overall survival (OS) will be estimated using Kaplan–Meier survival curves, and differences between study groups will be compared using the log-rank test. Survival probabilities at specific time points will also be calculated using Kaplan–Meier statistics. Univariate regression analysis will evaluate the predictive value of individual prognostic factors on outcomes. Multivariate Cox proportional hazards regression will be performed to assess the independent effect of multiple prognostic variables on survival outcomes. Missing data will be minimized through careful follow-up and data monitoring. The primary analysis will follow the intention-to-treat principle. When data are missing, multiple imputation techniques will be applied, and sensitivity analyses will be performed to evaluate the impact of missing data on study outcomes. A two-sided p-value < 0.05 will be considered statistically significant. All analyses will be conducted using STATA version 14. Ethics and dissemination The study will be conducted in accordance with the principles of the Declaration of Helsinki and applicable national ethical guidelines. Any protocol modifications that affect study conduct or the participant risk–benefit profile, including changes to objectives, design, sample size, participant eligibility, or major administrative aspects, will require approval from the respective Institutional Review Board or Ethics Committee. Minor corrections or clarifications that do not alter the study design or participant risk–benefit profile will be documented internally as administrative changes. The study investigators will have full access to and ownership of all data. De-identified data may be shared with other qualified investigators for secondary analyses upon reasonable request, provided the primary outcomes have been reported. Study findings will be disseminated through scientific and professional conferences and published in peer-reviewed journals. Discussion This study is designed to establish the efficacy and safety of the addition of bevacizumab to conventional induction chemotherapy in high-risk neuroblastoma patients. We hypothesize that the addition of bevacizumab to conventional induction chemotherapy will enhance response rates in high-risk neuroblastoma compared to conventional induction therapy alone. This anticipated improvement underscores the potential of integrating targeted anti-angiogenic therapy as a novel strategy to optimize treatment outcomes in this aggressive and therapeutically challenging malignancy. The BERNIE study investigated the addition of bevacizumab to multimodality therapy in children and adolescents with metastatic soft-tissue sarcoma (ages 6 months to < 18 years; n = 154). The study demonstrated that bevacizumab was well tolerated in combination with chemotherapy, with no treatment-related deaths and no increase in the incidence of grade 3/4 toxicities [31]. If this study demonstrates that adding bevacizumab to conventional chemotherapy improves response rates in high-risk neuroblastoma (HR-NB), we plan to adopt this protocol in clinical practice. Our goal is to enhance patient care by implementing a stratified and standardized approach to HR-NB treatment. This trial will provide patients with evidence-based standard therapy and facilitate the development of a uniform, nationwide protocol for neuroblastoma management. By establishing a standardized treatment framework grounded in robust research, we aim not only to improve outcomes for HR-NB patients but also to advance pediatric oncology and promote collaborative practices across the healthcare community. This study has several limitations. The open-label design may introduce performance and detection biases, potentially affecting subjective outcomes such as adverse event grading. Excluding patients with severe organ dysfunction or poor performance status limits the generalizability, as these populations are at higher risk for toxicity. The absence of intermediate endpoints, such as quality-of-life measures, restricts understanding of the broader impact of the intervention. Finally, the lack of a placebo group limits contextual evaluation of efficacy, and a deeper assessment of quality-of-life metrics would provide a more comprehensive view of treatment benefits. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1. Supplementary Material 1. Supplementary Material 2. Supplementary Material 2.